2. Signaling Pathways
  3. Immunology/Inflammation
  4. Macrophage migration inhibitory factor (MIF)

Macrophage migration inhibitory factor (MIF)

Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine encoded within a functionally polymorphic genetic locus. MIF is a highly conserved 12.5 kDa secretory protein that is involved in numerous biological processes. The expression and secretion profile of MIF suggests that MIF to be ubiquitously and constitutively expressed in almost all mammalian cells and is vital for numerous physiological processes. MIF is a pleiotropic inflammatory cytokine important in the upstream regulation of both innate and adaptive immunological responses and has been implicated in the pathogenesis of autoimmune diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Macrophage migration inhibitory factor (MIF) Related Products (23):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16692
    ISO-1
    		Inhibitor 99.94%
    ISO-1 is a macrophage migration inhibitory factor (MIF) antagonist with an IC50 of 7 μM.
    ISO-1
  • HY-110063
    4-IPP
    		Inhibitor 99.46%
    4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).
    4-IPP
  • HY-17009
    Iguratimod
    		Inhibitor 99.93%
    Iguratimod is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.
    Iguratimod
  • HY-110095
    (±)-CPSI-1306
    		Antagonist 98.90%
    (±)-CPSI-1306 is an orally available antagonist of macrophage migration inhibitory factor (MIF).
    (±)-CPSI-1306
  • HY-147390
    MIF098
    		Inhibitor 99.88%
    MIF098 is a macrophage migration inhibitory factor (MIF) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research.
    MIF098
  • HY-167880
    BMY-25551
    		Inhibitor
    BMY-25551 is a Mitomycin A (HY-130332) analogue that is 8 to 20 times more potent than Mitomycin C (HY-13316) in cytotoxicity to murine and human tumor cell lines. BMY-25551 can be utilized in cancer and hematologic depression research.
    BMY-25551
  • HY-159086
    RGB097
    		Inhibitor
    RGB097 is a potent D-dopachrome tautomerase (D-DT) inhibitor with an IC50 value of 0.5 µM. RGB097 has the potential for the research of cancer.
    RGB097
  • HY-P99262
    Imalumab
    		Inhibitor 98.37%
    Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer.
    Imalumab
  • HY-121356
    Carebastine
    		Inhibitor 99.23%
    Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner. Carebastine suppresses the expression of macrophage migration inhibitory factor.
    Carebastine
  • HY-115887
    R110
    		Inhibitor 99.90%
    R110 is a potent, competitive inhibitor of macrophage migration inhibitory factor 2 (MIF2) tautomerase with an IC50 of 15 μM. R110 has the potential for the research of cancer diseases.
    R110
  • HY-123814
    4-CPPC
    		Inhibitor 99.64%
    4-CPPC is a potent, reversible and selective MIF-2 inhibitor with Ki values of 431, 33 µM for MIF-1, MIF-2, respectively.
    4-CPPC
  • HY-W164560
    RDR 03785
    		Inhibitor
    RDR 03785 is a covalent MIF inhibitor with an IC50 of 0.36 μM.
    RDR 03785
  • HY-110084
    BTZO-1
    		Inhibitor 99.69%
    BTZO-1 binds to Macrophage migration inhibitory factor (MIF) with a Kd value of 68.6 nM, and its binding requires the N-terminal Pro1. BTZO-1 can activate antioxidant response element (ARE)-mediated gene expression and suppress oxidative stress-induced cardiomyocyte apoptosis in vitro.
    BTZO-1
  • HY-130332
    Mitomycin A
    		Inhibitor
    Mitomycin A is a bacterial metabolite. Mitomycin A reduces migration inhibition factor (MIF) production and can be used for the research of cancer.
    Mitomycin A
  • HY-148117
    MD13
    		Inhibitor
    MD13 is a macrophage migration inhibitory factor (MIF)-directed PROTAC with a Ki of 71 nM. MD13 can be used for cancer research.
    MD13
  • HY-149308
    MKA031
    		Inhibitor
    MKA031 (compound 6y) is a non-competitive MIF inhibitor with an IC50 value of 1.7 μM. MKA031 (compound 6y) interferes with MIF/AIF interaction, MIF nuclear translocation, and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced dependent cell death. MKA031 can be used in the study of chronic hepatitis C virus infection.
    MKA031
  • HY-144194
    MIF-IN-2
    		Inhibitor
    MIF-IN-2 is a migration inhibitory factor (MIF) inhibitor extracted from patent WO2021258272A1 compound 1. MIF-IN-2 can be used for the research of immune inflammation-related diseases.
    MIF-IN-2
  • HY-144196
    MIF-IN-4 hydrochloride
    		Inhibitor
    MIF-IN-4 hydrochloride is potent macrophage migration inhibitory factor (MIF) inhibitor (pIC50=5.01-6). MIF is a cytokine originally found to play a role in inhibiting macrophage migration.
    MIF-IN-4 hydrochloride
  • HY-146319
    MIF-IN-6
    		Inhibitor
    MIF-IN-6 (compound 2d) is a potent macrophage migration inhibitory factor (MIF) inhibitor with an IC50 of 1.4 μM and a Ki value of 0.96 μM, respectively. MIF-IN-6 attenuates MIF-induced ERK phosphorylation and inhibits proliferation of A549 cells.
    MIF-IN-6
  • HY-144190
    MIF-IN-1
    		Inhibitor
    MIF-IN-1 (compound 14) is a potent macrophage migration inhibitory factor (MIF) inhibitor (pIC50=6.87).
    MIF-IN-1